Carterra LSA Instrument

Carterra’s proprietary technology addresses a key objective of the pharmaceutical industry by helping to minimize the time it takes to develop new therapeutics.

SALT LAKE CITY (PRWEB)
January 14, 2020

Carterra® Inc., the world leader in high-throughput antibody screening and characterization, has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners. The additional funding will support the continued adoption of the innovative Carterra LSA™ high-throughput Surface Plasmon Resonance (HT-SPR) antibody screening platform and the development of new products and applications.

The Carterra LSA revolutionizes the drug discovery process by enabling higher information content assays earlier in the discovery process¬¬—during antibody screening. The LSA can measure binding kinetics and affinities of hundreds of interactions in parallel and perform comprehensive epitope binning experiments on up to 384 antibodies simultaneously. By conducting detailed antibody characterization during screening, the Carterra LSA increases the efficiency and productivity of lead selection and reduces costs during drug discovery and development.

“Carterra’s proprietary technology addresses a key objective of the pharmaceutical industry by helping to minimize the time it takes to develop new therapeutics,” said Matt Rice, Partner at Ballast Point Ventures. “We’re excited to provide resources and guidance as Carterra continues its growth.”

Carterra has seen rapid uptake of its LSA platform among large pharmaceutical companies, biotechs, contract research organizations, and academic labs since its launch in late 2018. “We are honored to work with Ballast Point Ventures and Telegraph Hill Partners in our mission to help scientists push the boundaries of scientific discovery.” said Carterra CEO, Josh Eckman. “Researchers are seeing how the Carterra LSA can significantly shorten the lead selection timeline and provide insights that were not previously possible.”

About Carterra, Inc.

Carterra® is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA™ instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City Utah, and has Customer Experience Centers in Dublin, California, Andover, Massachusetts and Munich, Germany. For additional information, please visit http://www.carterra-bio.com.

About Ballast Point Ventures

Ballast Point Ventures, headquartered in Tampa, Florida, is a later-stage venture capital and growth equity fund founded in 2002 to provide expansion capital for rapidly growing, privately owned companies in the healthcare, software and technology-enabled business services industries. For more information, please visit http://www.ballastpointventures.com.

About Telegraph Hill Partners

Telegraph Hill Partners, founded in 2001 and based in San Francisco and San Diego, CA, invests in innovative commercial stage life science, medical technology and healthcare companies. For more information please visit http://www.telegraphhillpartners.com.

Share article on social media or email:

It is a great privilege for our Cytonus team to be joined by such esteemed Key Opinion Leaders, each of whom has contributed important advances in the field of medicine

SAN DIEGO (PRWEB)
January 13, 2020

Cytonus Therapeutics Inc. today announces the formation of its Scientific Advisory Board (SAB) comprised of the industry’s key opinion leaders and distinguished research scientists, collectively representing prestigious academic institutions, immune-oncology centers, cell therapy centers, and private industry. Cytonus is a leading cell-based platform technology company focused on the development of a vast pipeline of proprietary cell lines called Cargocytes™, the next-generation of Adoptive Cellular Therapies (ACT) that have a wide range of medical applications across multiple therapeutic areas including immunotherapeutic products to cure difficult-to-treat cancers and inflammatory diseases, and to improve patient outcomes. Cytonus’ products have the potential to improve the health and lives of millions of people across the globe.

“It is a great privilege for our Cytonus team to be joined by such esteemed Key Opinion Leaders, each of whom has contributed important advances in the field of medicine,” commented Cytonus’ Founder and Chief Scientific Officer, Richard Klemke, PhD.

“The expertise and multi-disciplinary scientific perspectives of Dr. Hood, Dr. Lowy and Dr. Champlin will accelerate the advancement of Cytonus’ pipeline,” commented Cytonus’ Founder and CEO Remo Moomiaie-Qajar, MD.

The inaugural members of Cytonus’ Scientific Advisory Board are: Richard Champlin, MD; John Hood, PhD; and Andrew Lowy, MD.

• 
  Richard Champlin, MD is the Chair of MD Anderson Cancer Center’s Cellular Therapy Department. He also serves as Professor of Internal Medicine at University of Texas Health Science Center and is a Scientific Advisor for StemRad. Previously, in addition to serving on the President’s Advisory Board, Dr. Champlin has served as the Director of Transplantation Biology at UCLA’s Center for Health Sciences. He was the Founding President of the American Society of Blood and Marrow Transplantation, and is former President of the National Marrow Donor Program’s Council for Donor, Transplant and Collection Centers. Professor Champlin has received numerous industry recognitions, including: the Giannini Foundation Fellowship Award, the Waun Ki Hong Award for Excellence in Team Science; the Robert C. Hickey Chair in Clinical Cancer Care Award, and the G.A. Ross Scholarship Award.
• John Hood, PhD was Founder and Chief Executive Officer of Impact Biomedicines, which he successfully sold to Celgene for up to $7 Billion. He was also a founder of Endeavor Biomedicines, Neuronomix, and Samumed, where he advanced regenerative medicine and oncology therapies. Previously, Dr. Hood served as Director of Research at TargeGen, which sold to Sanofi SA after he co-invented its small molecule inhibitor, now known as fedratinib. Dr. Hood is a prolific inventor with more than 100 patents and has authored more than 100 scientific articles. He received both his PhD and Bachelor’s degree at Texas A&M University.
• Andrew Lowy, MD is the Chief of Surgical Oncology at UC San Diego, Moores Cancer Center. He is a distinguished surgical oncologist who is recognized worldwide for his expertise in the surgical treatment of gastrointestinal cancers. He is a key contributor to the development of heated intraperitoneal chemotherapy (HIPEC) to treat peritoneal based cancers. Dr. Lowy is the Co-Chair of the National Cancer Institute’s Pancreatic Cancer Task Force; serves as surgical liaison to one of the largest National Cancer Institute cooperative groups; and serves on the editorial board of the Annals of Surgical Oncology.

About Cytonus Therapeutics Inc.

Cytonus Therapeutics Inc. is a leading cell-based platform technology company focused on the development of a vast pipeline of proprietary cell lines called Cargocytes™, the next-generation of Adoptive Cellular Therapies (ACT) that have a wide range of medical applications across multiple therapeutic areas including immunotherapeutic products to cure difficult-to-treat cancers and inflammatory diseases, and to improve patient outcomes. Cytonus’ portfolio of inventions addresses recognized limitations of existing cell-based therapies. Cargocytes™ are cellular-engineered enucleated transporters of a multiplicity of therapeutic payloads to tissue in selective, potent, and controllable off-the-shelf cellular therapies. Cytonus’ extensive pipeline of products has the potential to treat numerous targeted diseases and to improve the health and lives of millions of people across the globe. For more information, please visit the Cytonus website at https://Cytonus.com and follow its LinkedIn and Twitter feed at: @Cytonus.

Statements in this news release, which relate to other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Follow Cytonus on LinkedIn and Twitter at: @Cytonus.

Share article on social media or email:

ARLINGTON, Va. (PRWEB)
January 10, 2020

Highly effective cancer therapies. Handheld hematology analyzers. A new and untapped world market. Social media selling life science tools. Science and Medicine Group publications, including Kalorama Information, Strategic Directions International (SDi), Bioinformatics, and IMV have made various projections for the new year in imaging, diagnostics, biotechnology, and life science instrument and supplies that can help marketers determine their plans next year. These projections are the result of analysis in the scores of detailed publications produced by these brands.

The list below includes the top 10 predictions for 2020:

1. CAR-T therapy revenue will exceed $1 billion next year: CAR-T cancer therapeutics, which use the patient’s own immune cells to attack cancer, will earn more than $700 million this year for the two companies that market them. And it’s likely these therapies will exceed $1 billion in revenue in 2020 as new products are approved. This is according to Kalorama Information. The reason is their track record in treating patients with little or no treatment options. CAR-T therapy involves using T cells from the patient and genetically engineering those cells using a disarmed virus so that the cells produce receptors called CARS that can attack cancer. It has shown effectiveness in some lymphomas and leukemias, and next year one or more products for myeloma are expected. Science and Medicine Group thought leaders and representatives were at the American Society of Hematology meeting in Orlando, FL, where significant studies were released on CAR-T safety and efficacy, as well as new products announced.

2. Social media will be the best tool for selling life science instruments: According to “Life Science Customer Purchasing Journey: Finding Customers Along the Way” scientists look to other scientists when they need a tool to solve an experimental problem. The report, which describes the purchasing habits of life science tool buyers, is the result of a survey of scientists. Among the findings were that 72% trust their colleagues over websites and 71% look to fellow scientists over sales reps. These are just two of the many facts detailed in the report. Instrument buyers will need to see feedback from their colleagues in order to be influenced in a purchase decision, according to the report. Social media reflects the best forum for this to happen. The report also gets into other topics and finds that good customer service will be essential for sales in 2020.

3. Instrument makers will target the ASEAN countries: The Association of Southeast Asian Nations (ASEAN) is a multinational economic and political alliance founded in 1967 by Thailand, the Philippines, Malaysia, Singapore, and Thailand. If the ASEAN group were a single nation, it would rank third in population, after India. It would also be the eighth largest market in the world. While not one nation, in 2015, the ASEAN Economic Community was established to create a single market for free trade of goods, services, and labor across the region, similar to the single market free trade within the European Union. According to SDi’s report on the Southeast Asia instrument markets, this group of Southeast Asian nations is projected to have the fastest growth in the analytical instrumentation market in the next five years due to its burgeoning pharma/bio sector. Furthermore, the ASEAN’s policies and foreign investments will bolster the pharma/bio sector contributing even more to the region’s growth. While places like Singapore and Taiwan have well-established pharma/bio industries, other countries like Thailand and Malaysia look to grow domestic production and research for pharmaceuticals.

4. Imaging procedure volume, especially for CT and MRI, will increase around the world: Results are in from IMV’s Global Radiologist Survey, part of its “Global Imaging Market Outlook Report“. Over 300 respondents participated in IMV’s global survey, and they represent key opinion leaders, with nearly half of the respondents being the chair/chief/heads of their radiology departments and over half being practicing radiologists. Overall, these opinion leaders are optimistic about the growth of imaging in their countries, with 80% saying their imaging procedure volume will increase. Respondents in the emerging markets are more optimistic about their outlook for increases in imaging procedures than those in the developed markets. The top two modalities planned in all 10 global regions are CT and MRI.

5. That doesn’t mean all global hospitals are ready: IMV’s survey also found that solutions to address this procedure growth may be a challenge. Only one-quarter of the respondents feel their “capacity is sufficient to meet their needs over the next two to three years,” but their prospects for acquiring imaging equipment may be inhibited by delays in their internal and governmental approval processes and local economic conditions. Respondents in Latin America, the Middle East, and Africa are particularly concerned about their local economy limiting their capital budgets for imaging equipment, and they are very cost-conscious about equipment and service pricing while seeking reliable equipment and responsive service in their environments.

6. Preparation for sequencing will be a $2 billion+ market: The increasingly routine use of sequencing in clinical settings is creating tremendous opportunities for suppliers of sequencing instrumentation and consumables, including those required for preanalytical preparation of samples from biological materials. In fact, clinical applications will drive double-digit growth for the NGS sample preparation market over the next five years. SDi’s newly published report, Sample Preparation for Next-Generation Sequencing, provides an in-depth analysis of how precision medicine and other applications are shaping demand for next-generation sequencing (NGS) sample preparation techniques. The report finds these products earned $1.8 billion this year and will push beyond $2 billion in 2020.

7. AI will find its best home in imaging: IMV’s Global Radiologists Survey findings also confirmed the future of artificial intelligence (AI) and machine-learning tools for imaging in 2020 and beyond. The top-ranked potential use for AI that respondents cited was “capabilities to more precisely diagnose patient conditions and enhance personalized medicine.” It’s not all positive — in their comments on potential uses, some radiologists see the potential for AI to improve clinical decision support and image quality, but others expressed concern on when and how AI applications will be integrated into their routine practice and daily workflow, as well as work seamlessly with their imaging equipment, PACS, and RIS.

8. Ascendance of mass spectrometry as a clinical instrument continues: Within the analytical instrumentation industry, mass spectrometry is certainly one of the most dynamic areas for growth over the next several years. Its increasingly sensitive analytical capabilities and enhancements continue to bring the technology to the edge of new scientific discovery and research applications. While SDi covers the market for eight separate mass spectrometry techniques in its flagship publication, the “Global Assessment Report,” it does so from a broad perspective that looks across all end markets. Clinical mass spectrometry, however, is one particular end market that has been at the root of very rapid mass spectrometry growth over the past few years — and will continue to be in 2020 and for the foreseeable future. SDi’s latest publication, “The 2019 Mass Spectrometry Market for Clinical Applications“, dives into the world of clinical diagnostics to examine how robust the demand from laboratories in this space is shaping the market for mass spectrometry technologies. The report presents market data and insights into six categories of clinical mass spectrometry, although two categories in particular are responsible for the most disruptive market influences in recent years: MALDI-TOF and triple quadrupole LC/MS.

9. Multiphoton microscopy makes gains: According to SDi’s “2019 Market for Live Cell Imaging” report, the total market for live cell imaging instruments, assays, and labeling reagents is projected to reach $1.9 billion in five years. Among the factors driving this high growth is the increasing adoption of advanced microscopy techniques for live cell imaging, namely multiphoton microscopy and light sheet microscopy. Multiphoton microscopy, also called two-photon excitation microscopy, makes use of nonlinear optics to provide finely localized, three-dimensional imaging. Instead of using optics to control the light returning to the detector, multiphoton optics ensure that the stimulated part of the sample is restricted to a small point, which reduces the risk of photobleaching effects. Light sheet microscopy, also called single-plane illumination microscopy, illuminates only a thin plane of just a few micrometers at a time using a laser. As the sample is moved through the light sheet, three-dimensional images are generated. Since only a thin slice of the sample is exposed at a time, light sheet microscopy is a relatively gentle technique for live cell imaging and can be used to image cells in living animals.

10. Hematology testing goes handheld: Hematology is important for a workup in annual exams and hospital inpatients. The basis of hematology testing is the complete blood count (CBC) that provides information on blood components: hemoglobin, hematocrit, red blood cells, white blood cells, reticulocytes, and platelets. Kalorama Information has covered hematology for decades in its “The Worldwide Market for In Vitro Diagnostic Tests” and says these devices are now getting smaller and useable at the point of care (POC) — a trend that will continue in 2020. A number of handheld and benchtop analyzers are available for POC professional hematology procedures. Among the producers of these products are Beckman Coulter, Diatron, GlysBy Diagnostics, HemoCue (Radiometer/Danaher), Horiba, Roche, and Sysmex. Hematology will remain the second-largest volume of global in vitro diagnostic procedures, with the number of tests increasing 5.3% per year to nearly 6.7 billion in 2024. The total worldwide volume of POC professional hematology testing procedures conducted is predicted to expand 4.4% annually to 424 million in 2024. Uses in general health screening and the diagnosis and monitoring of blood-related disorders during hospital stays, emergency room visits, and physicians’ consultations will account for growth. The availability of complete blood counts on high-throughput clinical chemistry systems will moderate a faster rise in procedure volume.

About Science and Medicine Group

Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Our clients, including some of the top Fortune 500 companies in the world, use our business intelligence, market research and publications, and marketing platforms to grow their businesses globally.

R3 Stem Cell Offers a Free Cryogenic Freezer Program to Partner Clinics

For practices that perform regenerative procedures on a regular basis, having a cryogenic freezer on site is a fantastic option. This will save practices a considerable amount on shipping, and help a lot to have product available when same day procedures are necessary.

PHOENIX (PRWEB)
January 09, 2020

R3 Stem Cell, the nation’s leader in regenerative therapies, is now offering its partner practices a complimentary freezer program. The cryogenic freezer allows practices to have plenty of stem cell and exosome biologics on hand for procedures.

The top stem cell and exosome biologics require cryogenic freezing. This may include a practice receiving the biologics with overnight shipping on dry ice, which can cost a considerable amount on a regular basis. For practices that perform regenerative procedures on a regular basis, having a cryogenic freezer on site is a fantastic option. This will save practices a considerable amount on shipping, and help a lot to have product available when same day procedures are necessary.

The cryogenic freezers offered are provided on a loaner basis for free. They reach temperatures below negative 80 degrees Celsius, and also come with a temperature probe for consistent monitoring. This is critical to making sure providers are warned if the power is disrupted.

R3 Stem Cell’s nationwide Centers of Excellence have performed over 13,000 regenerative procedures. No significant adverse events have been reported to date. R3 offers its partner practices considerable stem cell patient marketing, training, IRB approved research studies, first rate stem cell and exosome biologics along with a peer to peer network that is stellar.

To learn more about the stem cell freezer program, call R3 today at (844) GET-STEM.

Share article on social media or email:

Red Nucleus

“The addition of Red Nucleus R&D means we have the capability to provide comprehensive expert services that address R&D.” Ian Kelly, Red Nucleus, CEO.

YARDLEY, Pa. (PRWEB)
January 08, 2020

Pyxa Solutions, a leading provider of consulting, operational, and strategic services supporting life sciences teams, announced today that the company is rebranding as Red Nucleus R&D, a division of Red Nucleus. Red Nucleus is the premier provider of learning and performance solutions for the life sciences industry.

The addition of Red Nucleus R&D under the Red Nucleus brand expands the company’s reach into life sciences organizations and positions them to provide both commercial and R&D services and solutions.

Ian Kelly, Red Nucleus CEO, commented, “The Red Nucleus name has always been associated with award-winning learning solutions that support the commercial side of life sciences organizations. With the addition of Red Nucleus R&D, we now have the capability to provide comprehensive expert services that address R&D as well as commercial business challenges under one trusted name.”

The Red Nucleus R&D team consists of life sciences strategy and change, system and information management, and operations professionals with cross-functional expertise that spans R&D processes.

Dalia El-Sherif, PhD, Red Nucleus R&D Strategy and Change Partner, noted, “As Red Nucleus R&D, we will continue our tradition of delivering a broad range of differentiated and strategic services through our proprietary methodologies that aid clients in defining, building, and optimizing their R&D capabilities.”

Mike Swalina, Red Nucleus R&D Operations Partner, added, “Under the Red Nucleus umbrella, our combined clients can also expect to see a continuation of the high-touch engagement practices that have been the foundation for both companies as we have experienced rapid and continued growth.”

Red Nucleus is headquartered in Yardley, PA. The Red Nucleus R&D office will continue to operate out of its current location in Malvern, PA. The company also has offices in the United Kingdom, India, and Japan.

About Red Nucleus

Red Nucleus is the premier provider of strategic learning, performance, and process solutions exclusively for the life sciences industry. Our global solutions engage and inspire teams across the commercial and R&D spaces and are designed to boost understanding, efficacy, and compliance.

Squarely focused on the life sciences industry for more than 25 years, Red Nucleus takes pride in our long-term relationships with industry leaders, as well as our strategic partnerships with innovative startups. We are focused on developing thoughtful, high-quality solutions that are in accordance with each client’s unique culture and process. Our clients trust us to build impactful, award-winning programs that deliver actionable insights and measurable results.

Visit http://www.rednucleus.com to learn more.

Share article on social media or email:

Human Mesenchymal Stromal Cells transfer mitochondria to neighboring human islet beta cells in direct contact co-culture.

DURHAM, N.C. (PRWEB)
January 08, 2020

Allogenic transplantation of insulin-secreting islet β-cells offers the possibility of treating type 1 diabetes (T1D); however, the stress islets undergo during preparation for transplantation compromises their functional viability and poses a major obstacle to their adoption as a treatment for the majority of patients. A study released today in STEM CELLS offers information to help overcome this drawback.

Previous studies have shown that mouse mesenchymal stem cells (MSCs) can boost donor islet β-cells’ survival and function during the co-culturing process prior to transplantation. But the STEM CELLSSC study is the first to show that mitochondria – the organelles that power a cell — are what is behind the improvement.

“When mitochondria are impaired, islet β-cells can’t produce insulin effectively, and they also tend to die off. In our study, we addressed the hypothesis that the MSCs act as mitochondrial donors during the co-culturing process, transferring functional mitochondria directly to adjacent islets,” said Chloe Rackham, Ph.D., of the Department of Diabetes, Faculty of Life Sciences and Medicine, King’s College London, and lead investigator of the SC study.

Their hypothesis appears to be spot on. The study results showed that MSCs transfer mitochondria to islet β-cells during in vitro co-culture, a process that occurs at least partially through tunneling nanotube-like structures. This transfer correlated with an increase in islet mitochondrial oxygen consumption and enhanced glucose-induced insulin secretion.

“Other interesting results from the study show that mitochondrial transfer from human MSCs to human islets is more extensive than from mouse MSCs to mouse islets, most likely because isolated human islets are exposed to more extreme cellular stressors which initiate mitochondria transfer to human islets,” Dr. Rackham said.

These findings suggest that the mitochondrial donation capacity of MSCs should be harnessed to ensure the functional longevity of transplanted human islets in clinical protocols, she and her team concluded.

“The capability of mesenchymal stromal cells to transfer mitochondria into other cellular targets is highly interesting,” said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. “This is an important new report indicating a potential future therapeutic benefit to that biological phenomenon.”

The full article, “Optimizing beta cell function through mesenchymal stromal cell mediated mitochondria transfer,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3134.

Full caption for figure: Human Mesenchymal Stromal Cells transfer mitochondria to neighboring human islet beta cells in direct contact co-culture. Ensuring optimal beta cell mitochondrial mass and bioenergetics through MSC-mediated mitochondria transfer offers a novel strategy for improving the outcomes of clinical islet transplantation as a therapy for Type 1 Diabetes.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world’s first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.wiley.com.

Share article on social media or email:

The VivopureX™ antibody collection includes a selection of our most exciting mouse-anti-mouse antibodies, now available at discounted bulk prices ideal for in vivo researchers.

REDCAR, United Kingdom (PRWEB)
January 07, 2020

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. The antibodies are all available in discounted bulk sizes ranging from 1 mg to 100 mg.

VivopureX™ antibodies are species-matched chimeric antibodies, consisting of a clone’s original antigen-binding variable domain with a mouse constant domain, which means they do not induce neutralizing antibodies in mouse models. As a result, the engineered recombinant antibodies offer many advantages compared to the original monoclonal antibodies, including increased long-term efficacy, stronger potency and a more consistent response across cohorts. In addition, VivopureX™ antibodies feature engineered effector functions, with Fc receptor binding tailored to best suit popular applications such as depletion, agonism or blocking.

All antibodies are produced recombinantly for ensured batch-to-batch reproducibility, and offer high purity and low endotoxin levels ideal for in vivo applications. The antibodies are targeted against key immune system proteins, including clinically relevant checkpoint proteins such as PD-1, CTLA-4 and OX40. Absolute Antibody data has shown that the recombinant mouse PD-1 antibody, based on the widely used clone RMP1-14, reduces tumor size in a mouse model more effectively than the original rat version.

“The VivopureX™ antibody collection includes a selection of our most exciting mouse-anti-mouse antibodies, now available at discounted bulk prices ideal for in vivo researchers,” said Dr. Michael Fiebig, Director of Products and Innovations at Absolute Antibody. “Most antibodies currently used in vivo are immunogenic, leading to adverse immunological reactions and gradual loss of activity. By applying the same protein engineering approaches used in therapeutic development to research reagents, we can improve in vivo research results and further our understanding into the mechanisms underlying immunotherapy.”

For more information, and a full list of available antibody targets, please visit our website here.

About Absolute Antibody, Ltd.

Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Visit absoluteantibody.com for more information.

Contact:

Lisa Merolla    

Director of Marketing

+1 617-377-4057 (extension 610)

l.merolla@absoluteantibody.com

Share article on social media or email:

ISB President Dr. Jim Heath is pictured outside of ISB in the heart of South Lake Union in Seattle.

ISB is partnering with Town Hall Seattle for a speaker series focusing on some of the most important topics in science and health care.

SEATTLE (PRWEB)
January 02, 2020

ISB is celebrating its 20th anniversary with events throughout 2020. As part of this year-long celebration, ISB is partnering with Town Hall Seattle for a speaker series focusing on some of the most important topics in science and health care.

The first of these events will focus on brain health and will be held Thursday, March 5, 2020 in Town Hall Seattle’s Great Hall. Neuroscientist and New York Times bestselling author Dr. David Eagleman will deliver the keynote address and will take part in a panel discussion along with brain health expert Dr. Mary Kay Ross. Dr. Ross is founder and CEO of the Brain Health & Research Institute, which is a clinic that was co-founded by ISB this past September.

Other ISB-Town Hall Seattle events will focus on vaccines, STEM education and artificial intelligence in health care, and will feature notable experts in each field. More details will be available very soon.

In 2000, Drs. Lee Hood, Ruedi Aebersold and Alan Aderem created ISB as the first-ever institute dedicated to systems biology. For the past two decades, our scientists have been on the ground floor on many important research areas — aging and wellness, computational biology, brain diseases, and many chronic and infectious diseases, to name a few. Furthermore, ISB has improved the quality of and accessibility to STEM education through curriculum development and by working with entire school systems to get students thinking like scientists.

ISB remains at the cutting edge of science. Our research is focused on using the tools of systems biology to define an individual’s state of wellness, to detect early transitions to disease, and to develop proactive interventions designed to prevent the full development of disease. We believe every patient is unique, and our affiliation with Providence St. Joseph Health, one of the nation’s largest not-for-profit health care systems, provides a pipeline to rapidly move developments from the research bench to a patient’s bedside.

Our labs are working on big problems such as developing personalized cancer treatments and harnessing an individual’s immune system to fight disease, slowing the progression of Alzheimer’s Disease and other neurodegenerative diseases, embracing machine learning to create biomedical, interpretable risk models for clinical decision support, and much more.

Share article on social media or email:

Chelonian Conservation and Biology Volume 18 Issue 2

“Sometimes even what might appear to be basic information (such as how many tortoises reside in an area, how they interact with each other and how far and how often they roam) can be difficult to determine because tortoises are elusive.

LAWRENCE, Kan. (PRWEB)
December 31, 2019

Chelonian Conservation and Biology—The Mojave Desert tortoise may be an icon of its ecoregion, but researchers struggle to gather even basic information about this shy, burrowing reptile. Its scat, however, is easy to find and collect. The stool can be used to identify individual animals, allowing agencies to monitor this threatened, federally protected species.

As reported in the current issue of Chelonian Conservation and Biology, researchers from the U.S. Geological Survey and University of Nevada, Reno, compared protocols for extracting DNA from scat samples to determine the genetic makeup of individual tortoises and identify the ideal method for desert tortoise studies. Such scat genotyping has been helpful in studying mammals, and the technique is touted as being non-invasive to animals and their habitats. Until now, relatively few studies have applied it to tortoises.

“Sometimes even what might appear to be basic information (such as how many tortoises reside in an area, how they interact with each other and how far and how often they roam) can be difficult to determine because tortoises are elusive,” said researcher Amy Vandergast. “Their sign, including scat, can be easier to find. Because all individuals shed epithelial cells in their stool, scat that is found during field surveys provides another means of identifying individuals using molecular markers.”

The researchers tested six DNA extraction protocols on scat samples collected from a threatened tortoise species, Gopherus agassizii, in the Mojave Desert area in southern Nevada and California. They aimed to find out whether they could accurately identify individual tortoises from stool samples and hoped to pinpoint the ideal tool for genotyping the samples and using the genetic markers to monitor tortoise populations.

The study found that sample quality was paramount; the caliber of the genotype depended more heavily on the quality of the DNA sample than the type of extraction method used. Despite a relatively small sample size, 30 percent of field-collected scat and 70 percent of fresh scat were genotyped accurately. The researchers decided that the Qiagen DNeasy Plant Mini extraction kit extracts DNA most efficiently from tortoise scat.

The results of the study indicate that collecting scat in the field and analyzing the DNA can supplement standard survey and monitoring techniques. With additional information from the DNA extracted from scat, researchers and management agencies could learn more about the population dynamics, relationships and movements of individuals throughout the tortoise species’ range.

Full text of the article “Development of a Genotyping Protocol for Mojave Desert Tortoise Scat,” Chelonian Conservation and Biology, Vol. 18, No. 2, 2019, is now available at https://www.chelonianjournals.org/doi/full/10.2744/CCB-1394.1.

About Chelonian Conservation and Biology

Chelonian Conservation and Biology is an international scientific journal of turtle and tortoise research. Its objective is to share any aspects of research on turtles and tortoises. Of special interest are articles dealing with conservation biology, systematic relationships, chelonian diversity, geographic distribution, natural history, ecology, reproduction, morphology and natural variation, population status, husbandry, community conservation initiatives and human exploitation or conservation management issues. For more information, please visit [http://www.chelonian.org/.

Share article on social media or email: